Although ROS TKI drugs have been approved, there are still unmet treatment needs in the clinic, such as the proportion of brain metastases in patients who have failed firstgeneration ROS TKI treatment has increased to as high as and the occurrence of GR resistance. The new generation of ROS TKI has a significant therapeutic effect on brain lesions and can overcome GR resistance. In the whole management of ROSpositive NSCLC patients, the firstline application of the new generation of ROS TKI will bring longer progressionfree survival and bring longer survival benefits to patients.
Talorente is an oral, potent, brainpenetrant, selective, nextgeneration, potentially saudi arabia phone number list bestinclass ROS inhibitor. Talorente is being evaluated in two Phase clinical studies in patients with ROSpositive nonsmall cell lung cancer: TRUSTI NCT in China and TRUSTII NCT, a global pivotal clinical study.
Dabolu® is approved by the China National Medical Products Administration NMPA for: the treatment of adult patients with ROSpositive locally advanced or metastatic nonsmall cell lung cancer NSCLC that has progressed after ROSTKI treatment; and the treatment of adult patients with ROSpositive locally advanced or metastatic nonsmall cell lung cancer NSCLC.